|
Orthologous residues
|
|
PPP1R1A (human): S6‑p, PPP1R1A (mouse): S6‑p, PPP1R1A (rat): S6‑p, PPP1R1A (rabbit): S6‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
'brain, cortex', 'brain, hippocampus', 'brain, striatum', PC-12 (chromaffin)
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
mouse, rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
PHOSPHATASE
|
PPP1CA (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
CDK5 (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
PHOSPHATASE
|
PPP2R5A (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
roscovitine
|
|
|
|
decrease
|
|
|
butyrolactone
|
|
|
|
decrease
|
|
|
U0126
|
|
|
|
no change compared to control
|
|
|
indolinone A
|
|
|
|
decrease
|
|
|
indolinone B
|
|
|
|
no change compared to control
|
|
|
fostriecin
|
|
|
|
increase
|
|
|
neurabin
|
|
|
|
increase
|
|
|
cyclosporin A
|
|
|
|
no change compared to control
|
|
|
okadaic acid
|
|
|
|
increase
|
|
|
NMDA
|
|
|
|
decrease
|
|
|
forskolin
|
|
|
|
increase
|
|
|
